(Q34768779)

4 August 2017

1 reference

title

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib (English)

1 reference

4 August 2017

1 reference

1 reference

3

1 reference

4 August 2017

Oliver Hantschel

1

0 references

author name string

Uwe Rix

series ordinal

2

1 reference

PubMed ID

18398720

4 August 2017

language of work or name

1 reference

1 April 2008

1 reference

4 August 2017

1 reference

4 August 2017

49

1 reference

4 August 2017

615-619

1 reference

4 August 2017

4

1 reference

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

4 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Structural basis for the autoinhibition of c-Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Characterisation of kinase-selective inhibitors by chemical proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Rediscovering the sweet spot in drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801896103

10.1080/10428190801896103

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

18398720